Irinotecan in the treatment of glioma patients

This publication has 39 references indexed in Scilit:

• A phase III study of radiation therapy plus carmustine with or without recombinant interferon-? in the treatment of patients with newly diagnosed high-grade glioma
  Cancer, 2001
• Chemotherapy of brain tumors
  Current Opinion in Neurology, 2000
• Chemotherapy for high-grade gliomas
  British Journal of Cancer, 2000
• Multicenter Phase II Trial of Temozolomide in Patients With Anaplastic Astrocytoma or Anaplastic Oligoastrocytoma at First Relapse
  Journal of Clinical Oncology, 1999
• Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials
  Journal of Clinical Oncology, 1999
• Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism
  Clinical Pharmacology & Therapeutics, 1999
• UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan
  Annals of Oncology, 1998
• Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy*
  Clinical Pharmacology & Therapeutics, 1997
• Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults
  Cancer, 1993
• Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas
  Journal of Neurosurgery, 1978